CXI Healthcare Technology Group Inkomsten in het verleden
Verleden criteriumcontroles 4/6
CXI Healthcare Technology Group has been growing earnings at an average annual rate of 70.7%, while the Personal Products industry saw earnings growing at 9.9% annually. Revenues have been declining at an average rate of 7% per year. CXI Healthcare Technology Group's return on equity is 6.1%, and it has net margins of 42.3%.
Belangrijke informatie
70.7%
Groei van de winst
69.3%
Groei van de winst per aandeel
| Personal Products Groei van de industrie | 3.8% |
| Inkomstengroei | -7.0% |
| Rendement op eigen vermogen | 6.1% |
| Nettomarge | 42.3% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Insufficient Growth At CXI Healthcare Technology Group Limited (KOSDAQ:900120) Hampers Share Price
Sep 30
CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital
Aug 05Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S
May 30How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 02Opbrengsten en kosten
Hoe CXI Healthcare Technology Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 69,420 | 29,349 | 5,600 | 4,939 |
| 31 Mar 24 | 67,194 | 21,013 | 3,401 | 5,231 |
| 31 Dec 23 | 68,673 | 17,446 | 4,305 | 5,611 |
| 30 Sep 23 | 69,715 | 12,117 | 6,971 | 7,873 |
| 30 Jun 23 | 71,617 | 7,528 | 10,442 | 9,750 |
| 31 Mar 23 | 79,065 | 1,294 | 13,352 | 12,812 |
| 31 Dec 22 | 87,718 | 3,198 | 13,294 | 13,550 |
| 30 Sep 22 | 98,052 | 9,532 | 12,327 | 9,969 |
| 30 Jun 22 | 101,376 | 5,981 | 12,437 | 9,317 |
| 31 Mar 22 | 103,312 | 6,182 | 13,586 | 5,963 |
| 31 Dec 21 | 105,354 | 4,302 | 14,554 | 3,998 |
| 30 Sep 21 | 108,284 | 2,762 | 15,390 | 5,424 |
| 30 Jun 21 | 104,593 | 5,098 | 12,846 | 3,818 |
| 31 Mar 21 | 81,035 | -55,823 | 17,799 | 6,389 |
| 31 Dec 20 | 64,812 | -70,201 | 23,388 | 9,016 |
| 30 Sep 20 | 63,264 | -83,142 | 30,209 | 9,995 |
| 30 Jun 20 | 63,406 | -98,437 | 39,211 | 10,858 |
| 31 Mar 20 | 82,358 | -61,945 | 44,740 | 9,371 |
| 31 Dec 19 | 106,374 | -64,559 | 50,190 | 8,496 |
| 30 Sep 19 | 117,046 | -67,216 | 52,472 | 9,575 |
| 30 Jun 19 | 129,309 | -70,621 | 54,781 | 11,801 |
| 31 Mar 19 | 147,921 | -64,977 | 55,239 | 13,323 |
| 31 Dec 18 | 149,568 | -66,308 | 57,169 | 13,316 |
| 30 Sep 18 | 148,347 | -72,578 | 60,733 | 13,198 |
| 30 Jun 18 | 145,264 | -73,933 | 62,473 | 12,874 |
| 31 Mar 18 | 120,456 | -70,977 | 58,424 | 11,190 |
| 31 Dec 17 | 120,228 | -49,884 | 51,365 | 9,909 |
| 30 Sep 17 | 125,336 | -24,445 | 46,229 | 7,972 |
| 30 Jun 17 | 146,319 | 786 | 41,966 | 6,210 |
| 31 Mar 17 | 190,109 | 18,964 | 47,108 | 6,736 |
| 31 Dec 16 | 228,969 | 29,945 | 54,039 | 7,269 |
| 30 Sep 16 | 269,185 | 42,624 | 57,943 | 7,848 |
| 30 Jun 16 | 297,600 | 52,396 | 62,255 | 8,734 |
| 31 Mar 16 | 311,164 | 60,931 | 61,307 | 8,804 |
| 31 Dec 15 | 318,262 | 66,823 | 58,631 | 9,212 |
| 30 Sep 15 | 321,330 | 71,473 | 58,068 | 9,382 |
| 30 Jun 15 | 317,895 | 73,452 | 55,460 | 9,495 |
| 31 Mar 15 | 312,412 | 69,309 | 56,652 | 9,843 |
| 31 Dec 14 | 303,794 | 68,530 | 52,573 | 9,487 |
| 30 Sep 14 | 291,664 | 65,401 | 49,554 | 9,258 |
| 30 Jun 14 | 286,376 | 63,604 | 48,559 | 8,595 |
| 31 Mar 14 | 285,469 | 66,365 | 45,229 | 7,919 |
| 31 Dec 13 | 279,352 | 62,672 | 45,690 | 7,818 |
Kwaliteitswinsten: A900120 has a large one-off gain of ₩10.3B impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: A900120's current net profit margins (42.3%) are higher than last year (10.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: A900120 has become profitable over the past 5 years, growing earnings by 70.7% per year.
Versnelling van de groei: A900120's earnings growth over the past year (289.9%) exceeds its 5-year average (70.7% per year).
Winst versus industrie: A900120 earnings growth over the past year (289.9%) exceeded the Personal Products industry 30.2%.
Rendement op eigen vermogen
Hoge ROE: A900120's Return on Equity (6.1%) is considered low.